

**Author(s):**  
**Question:** CSBM responder compared to placebo for chronic constipation  
**Setting:**  
**Bibliography:** . linaclotide for chronic constipation. Cochrane [ ] [ ] [ ].

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CSBM responder	placebo	Relative (95% CI)	Absolute (95% CI)		
<b>CSBM responder rate: linacotide vs placebo</b>												
7	randomised trials	not serious	not serious	not serious	not serious	none	573/2615 (21.9%)	89/1234 (7.2%)	<b>OR 3.59</b> (2.82 to 4.57)	<b>146 more per 1,000</b> (from 108 more to 190 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: extremely low dose group vs low dose group</b>												
3	randomised trials	not serious	not serious	not serious	not serious	none	102/552 (18.5%)	102/538 (19.0%)	<b>OR 0.93</b> (0.67 to 1.27)	<b>11 fewer per 1,000</b> (from 54 fewer to 39 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: extremely low dose group vs high dose group</b>												
2	randomised trials	not serious	not serious	not serious	not serious	none	51/141 (36.2%)	62/138 (44.9%)	<b>OR 0.63</b> (0.38 to 1.05)	<b>110 fewer per 1,000</b> (from 213 fewer to 12 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: low dose group vs medium dose group</b>												
5	randomised trials	not serious	not serious	not serious	not serious	none	151/710 (21.3%)	162/712 (22.8%)	<b>OR 0.92</b> (0.71 to 1.19)	<b>14 fewer per 1,000</b> (from 55 fewer to 32 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: low dose group vs high dose group</b>												
2	randomised trials	not serious	not serious	not serious	not serious	none	47/127 (37.0%)	62/138 (44.9%)	<b>OR 0.69</b> (0.42 to 1.15)	<b>89 fewer per 1,000</b> (from 194 fewer to 35 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: medium dose group vs high dose group</b>												
2	randomised trials	not serious	not serious	not serious	not serious	none	56/135 (41.5%)	57/139 (41.0%)	<b>OR 1.03</b> (0.63 to 1.68)	<b>7 more per 1,000</b> (from 106 fewer to 129 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: extremely low dose group vs placebo</b>												
3	randomised trials	not serious	serious	not serious	not serious	publication bias strongly suspected	106/552 (19.2%)	45/550 (8.2%)	<b>OR 2.94</b> (1.98 to 4.34)	<b>126 more per 1,000</b> (from 68 more to 197 more)	⊕⊕○○ LOW	CRITICAL
<b>CSBM responder rate: low dose group vs placebo</b>												
6	randomised trials	not serious	not serious	not serious	not serious	none	202/1121 (18.0%)	78/1145 (6.8%)	<b>OR 3.24</b> (2.44 to 4.31)	<b>123 more per 1,000</b> (from 83 more to 171 more)	⊕⊕⊕⊕ HIGH	CRITICAL
<b>CSBM responder rate: medium dose group vs placebo</b>												
5	randomised trials	not serious	serious	not serious	not serious	none	162/712 (22.8%)	59/644 (9.2%)	<b>OR 3.08</b> (1.46 to 6.50)	<b>145 more per 1,000</b> (from 37 more to 304 more)	⊕⊕⊕○ MODERATE	CRITICAL
<b>CSBM responder rate: high dose group vs placebo</b>												
3	randomised trials	not serious	not serious	not serious	not serious	publication bias strongly suspected	103/230 (44.8%)	37/238 (15.5%)	<b>OR 4.79</b> (3.04 to 7.54)	<b>313 more per 1,000</b> (from 203 more to 426 more)	⊕⊕⊕○ MODERATE	CRITICAL

**CI:** Confidence interval; **OR:** Odds ratio